Investors

Vasomune Therapeutics has been working with University of Iowa Pharmaceuticals (UIP) through a strategic partnership toward the manufacture of AV-001, a biopharmaceutical therapeutic that treats

Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001 for the Treatment of ALI/ARDS of Any Cause,

Vasomune Therapeutics Announces Clinical and Scientific Advisory Board  Esteemed Leaders in Translation, Therapeutic Development and Critical Care Medicine  TORONTO, Ontario – (Business Wire) – May

Vasomune Therapeutics Appoints Meenu Chhabra to its Board of Directors  Industry Leader Joins Vasomune’s Board of Directors as the Company Transitions to Clinical Development of AV-001